



Figure A3. Progression-free survival with respect to *MGMT* promoter methylation.

A: Patients with glioblastoma, IDH-wildtype: *MGMT*-methylated vs. *MGMT*-unmethylated.



B: Patients with glioblastoma, IDH-wildtype, *MGMT*-methylated: temozolomide and radiotherapy vs. only radiotherapy.



C: Patients with glioblastoma, IDH-wildtype, *MGMT*-unmethylated: temozolomide and radiotherapy vs. only radiotherapy.

